Dr. Do is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 TECHNOLOGY SQUARE
Cambridge, MA 02139Phone+1 617-528-8375
Summary
- I am a board certified oncologist specializing in early drug development. I completed by training at the National Cancer Institute, National Institutes of Health.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2010 - 2014- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2014
George Washington UniversityResidency, Internal Medicine, 2006 - 2009- George Washington University School of Medicine and Health SciencesClass of 2006
Certifications & Licensure
VA State Medical License 2009 - 2026
MA State Medical License 2014 - 2025
NH State Medical License 2024 - 2024
DC State Medical License 2006 - 2009- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Start of enrollment: 2020 Sep 01
Publications & Presentations
PubMed
- 24 citationsSynergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancersJosephine Hai, Shengwu Liu, Lauren E. Bufe, Khanh T. Do, Ting Chen
Clinical Cancer Research. 2017-11-15 - 5 citationsCombination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.S. Kummar, Apurva K. Srivastava, Tony Navas, Fabiola Cecchi, Young H. Lee
Investigational New Drugs. 2021-06-28 - 10 citationsA Phase I study of DLYE5953A, an anti-LY6E antibody covalently linked to monomethyl auristatin E, in patients with refractory solid tumorsSara M. Tolaney, Khanh T. Do, Joseph Paul Eder, Patricia LoRusso, Colin D. Weekes
Clinical Cancer Research. 2020-07-21
Lectures
- Phase 1 Safety, Pharmacokinetic, and Pharmacodynamic Study of Fadraciclib (CYC065), a cyclin-dependent kinase inhibitor, in Patients with Advanced Solid Tumors32nd EORTC/AACR/NCI Virtual Symposium 24-25 October 2020 - 10/25/2020
- Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumorsAACR Annual Meeting - Atlanta, GA 2019 - 4/2/2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
